Loading...

Heron Therapeutics

DB:AXD2
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AXD2
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
AXD2 Share Price and Events
7 Day Returns
-5.4%
DB:AXD2
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-14.5%
DB:AXD2
-10.2%
DE Biotechs
-6%
DE Market
AXD2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Heron Therapeutics (AXD2) -5.4% -4% -12.3% -14.5% 3.7% -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • AXD2 underperformed the Biotechs industry which returned -10.2% over the past year.
  • AXD2 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
AXD2
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Heron Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Heron Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €20.47.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Heron Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Heron Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AXD2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.44
NasdaqCM:HRTX Share Price ** NasdaqCM (2019-04-18) in USD $23.5
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Heron Therapeutics.

DB:AXD2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:HRTX Share Price ÷ EPS (both in USD)

= 23.5 ÷ -2.44

-9.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Heron Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Heron Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Heron Therapeutics's expected growth come at a high price?
Raw Data
DB:AXD2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
61.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Heron Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Heron Therapeutics's assets?
Raw Data
DB:AXD2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.74
NasdaqCM:HRTX Share Price * NasdaqCM (2019-04-18) in USD $23.5
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:AXD2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:HRTX Share Price ÷ Book Value per Share (both in USD)

= 23.5 ÷ 4.74

4.96x

* Primary Listing of Heron Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Heron Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Heron Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Heron Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Heron Therapeutics expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Heron Therapeutics expected to grow at an attractive rate?
  • Heron Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Heron Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Heron Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AXD2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AXD2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 61.1%
DB:AXD2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 38.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AXD2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AXD2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 926 596 445 7
2022-12-31 751 497 331 7
2021-12-31 543 497 176 8
2020-12-31 332 121 42 10
2019-12-31 154 35 -125 10
DB:AXD2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 77 -192 -179
2018-09-30 59 -205 -192
2018-06-30 47 -210 -195
2018-03-31 39 -181 -199
2017-12-31 31 -170 -197
2017-09-30 22 -162 -183
2017-06-30 13 -157 -190
2017-03-31 5 -152 -190
2016-12-31 1 -134 -173
2016-09-30 -119 -156
2016-06-30 -102 -131
2016-03-31 -91 -110

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Heron Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Heron Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AXD2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Heron Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AXD2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.95 7.45 2.78 7.00
2022-12-31 3.69 6.03 2.24 7.00
2021-12-31 2.42 5.91 1.29 8.00
2020-12-31 0.66 1.65 0.30 7.00
2019-12-31 -1.63 -0.98 -2.18 10.00
DB:AXD2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.44
2018-09-30 -2.82
2018-06-30 -3.14
2018-03-31 -3.46
2017-12-31 -3.65
2017-09-30 -3.70
2017-06-30 -4.15
2017-03-31 -4.58
2016-12-31 -4.57
2016-09-30 -4.21
2016-06-30 -3.60
2016-03-31 -3.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Heron Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Heron Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Heron Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Heron Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Heron Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Heron Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Heron Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Heron Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Heron Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Heron Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AXD2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 77.47 -178.84 93.37
2018-09-30 58.68 -191.77 87.22
2018-06-30 47.47 -195.29 83.64
2018-03-31 38.70 -199.42 83.86
2017-12-31 30.77 -197.48 82.16
2017-09-30 21.99 -182.96 77.85
2017-06-30 13.42 -189.60 75.35
2017-03-31 4.91 -190.03 70.18
2016-12-31 1.28 -173.14 69.03
2016-09-30 -156.42 65.29
2016-06-30 -130.59 56.05
2016-03-31 -110.47 47.11
2015-12-31 -97.59 35.74
2015-09-30 -86.97 27.96
2015-06-30 -83.50 23.93
2015-03-31 -79.40 21.61
2014-12-31 -76.37 19.73
2014-09-30 -69.79 21.51
2014-06-30 -63.47 23.73
2014-03-31 -59.87 23.62
2013-12-31 -55.28 23.54
2013-09-30 -50.07 19.94
2013-06-30 -43.44 15.92
2013-03-31 -32.55 12.83
2012-12-31 -24.43 9.76
2012-09-30 0.00 -19.77 6.44
2012-06-30 0.00 -17.67 5.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Heron Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Heron Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Heron Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Heron Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Heron Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Heron Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Heron Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Heron Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Heron Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Heron Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 97.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Heron Therapeutics Company Filings, last reported 3 months ago.

DB:AXD2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 370.16 4.57 332.37
2018-09-30 406.81 4.34 364.80
2018-06-30 431.89 29.11 422.96
2018-03-31 92.21 28.89 113.94
2017-12-31 131.14 28.68 172.38
2017-09-30 40.05 28.48 74.02
2017-06-30 69.08 28.29 109.26
2017-03-31 102.16 53.10 165.22
2016-12-31 -21.25 52.91 51.14
2016-09-30 17.88 52.73 88.92
2016-06-30 57.84 2.56 74.64
2016-03-31 92.68 2.39 100.41
2015-12-31 118.11 2.22 131.17
2015-09-30 141.70 2.06 152.99
2015-06-30 159.87 1.90 171.53
2015-03-31 48.00 1.75 55.56
2014-12-31 63.06 1.60 72.68
2014-09-30 81.01 1.45 86.21
2014-06-30 97.85 1.31 105.01
2014-03-31 55.41 1.16 57.48
2013-12-31 68.95 1.03 72.29
2013-09-30 20.87 0.89 22.60
2013-06-30 28.50 0.75 34.85
2013-03-31 41.38 0.62 45.72
2012-12-31 51.82 0.49 53.51
2012-09-30 57.52 0.37 60.05
2012-06-30 11.12 0.24 12.44
  • Heron Therapeutics's level of debt (1.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1.5% vs 1.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Heron Therapeutics has sufficient cash runway for 1.7 years based on current free cash flow.
  • Heron Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 29% each year.
X
Financial health checks
We assess Heron Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Heron Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Heron Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Heron Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Heron Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Heron Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Heron Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AXD2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AXD2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Heron Therapeutics has not reported any payouts.
  • Unable to verify if Heron Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Heron Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Heron Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Heron Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Heron Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Heron Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Heron Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Heron Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Barry Quart
COMPENSATION $4,243,100
AGE 61
TENURE AS CEO 5.9 years
CEO Bio

Dr. Barry D. Quart, Pharm.D., has been the Chief Executive Officer of Heron Therapeutics, Inc. since May 02, 2013 and has been its Director since June 2012. He also serves as President at Heron Therapeutics, Inc. from February 2019. Dr. Quart serves as the Scientific Advisor of Napo Pharmaceuticals, Inc. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. Dr. Quart’s qualifications to serve on Heron Board include his experience in senior management and as a Director with other biotechnology and pharmaceutical companies and his prior drug development experience. Dr. Quart was Principal Financial Officer and Principal accounting officer at Heron Therapeutics since April 1, 2017 until April 24, 2017. He served as the Chief Executive Officer and President at Ardea Biosciences, Inc. since December 21, 2006 until 2013, which he co-founded in 2006. He served as the President of Napo Pharmaceuticals Inc. from June 2002 to July 31, 2006 and served as its Chief Scientific Officer until July 31, 2006. He served as the President and Chief Executive Officer of Intrabiotics Pharmaceuticals Inc. since December 22, 2006. He served as Senior Vice President of Pfizer Global Research and Development. He served as Senior Vice President and Head of Drug Development for Agouron Pharmaceuticals Inc., a division of the Warner-Lambert Company, since 1997 and also served as its President of Research and Development. since 1999, where he was instrumental in the development and registration of Viracept, which went from the lab bench to NDA approval in 38 months. Dr. Quart served as Vice President of Regulatory Affairs for Agouron Pharmaceuticals Inc. since joining it in 1993. He served as an Executive Director of international regulatory affairs for Bristol-Myers Squibb Company since 1992. Dr. Quart served with Bristol-Myers Squibb for ten years experience in both Clinical Research and Regulatory Affairs, where he was actively involved in the development and registration of nine important drugs, including paclitaxel, didanosine, stavudine and sotalol. Within the newly created Pfizer Global Research and Development Division, he served as Senior Vice President of La Jolla Laboratories. He serves as a Director of NeuroGenetic Pharmaceuticals, Inc. He serves as a Director at Kiniksa Pharmaceuticals, Ltd. since October 2015. He was a Director of Ardea Biosciences, Inc. since December 21, 2006 until 2012. Dr. Quart served as a Director of Trimeris Inc. since June 2007 and Synageva BioPharma Corp. from June 2007 to June 22, 2015. He served as a Director of Napo Pharmaceuticals Inc. from May 2, 2002 to July 7, 2006. He served as an Executive Director of Intrabiotics Pharmaceuticals Inc. since December 22, 2006. He served as a Director of the La Jolla Laboratories. Dr. Quart received a Pharm.D. in clinical pharmacy from the University of California, San Francisco.

CEO Compensation
  • Barry's compensation has increased whilst company is loss making.
  • Barry's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Heron Therapeutics management team in years:

3.2
Average Tenure
56.5
Average Age
  • The tenure for the Heron Therapeutics management team is about average.
Management Team

Barry Quart

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
61
TENURE
5.9 yrs

Robert Hoffman

TITLE
CFO & Senior VP of Finance
COMPENSATION
$2M
AGE
52
TENURE
2 yrs

Kimberly Manhard

TITLE
Executive Vice President of Drug Development
COMPENSATION
$2M
AGE
58
TENURE
3.3 yrs

David Szekeres

TITLE
Senior VP of Business Development
AGE
44
TENURE
3.1 yrs

Sean Ristine

TITLE
Vice President of Human Resources
AGE
48
TENURE
3.6 yrs

Tom Ottoboni

TITLE
Chief Scientific Officer & Senior VP of Pharmaceutical and Translational Sciences
AGE
59
TENURE
4.8 yrs

Jesse Hollingsworth

TITLE
Senior Vice President of Oncology Franchise

Anita Gupta

TITLE
Senior Vice President of Medical Strategy & Government Affairs
TENURE
1.7 yrs

Paul Blake

TITLE
Chief Medical Officer
AGE
70
TENURE
1.3 yrs

Mike Mathews

TITLE
Senior Vice President of Pain Franchise
AGE
55
Board of Directors Tenure

Average tenure and age of the Heron Therapeutics board of directors in years:

5.3
Average Tenure
56
Average Age
  • The tenure for the Heron Therapeutics board of directors is about average.
Board of Directors

Kevin Tang

TITLE
Chairman of the Board
COMPENSATION
$176K
AGE
51
TENURE
6.8 yrs

Barry Quart

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
61
TENURE
6.8 yrs

John Poyhonen

TITLE
Director
COMPENSATION
$252K
AGE
58
TENURE
5.3 yrs

Craig Johnson

TITLE
Director
COMPENSATION
$330K
AGE
56
TENURE
5.3 yrs

Christian Waage

TITLE
Director
COMPENSATION
$235K
AGE
51
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Sep 18 Sell Tang Capital Management, LLC Company 12. Sep 18 12. Sep 18 -2,695,000 €30.72 €-82,780,698
X
Management checks
We assess Heron Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Heron Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company’s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Details
Name: Heron Therapeutics, Inc.
AXD2
Exchange: DB
Founded: 1983
$1,633,699,415
78,181,651
Website: http://www.herontx.com
Address: Heron Therapeutics, Inc.
4242 Campus Point Court,
Suite 200,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM HRTX Common Stock Nasdaq Capital Market US USD 26. Aug 1987
DB AXD2 Common Stock Deutsche Boerse AG DE EUR 26. Aug 1987
LSE 0J4V Common Stock London Stock Exchange GB USD 26. Aug 1987
Number of employees
Current staff
Staff numbers
198
Heron Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:22
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.